CPT code 86038 – Antinuclear antibody screen

Key takeaways

CPT code 86038 covers the qualitative ANA test by any method, with IFA as the common method. It reports presence or absence, not a titer.

86039 is the companion titer code, and billing both on the same day needs separate clinical justification and may trigger NCCI bundling review.

Medicare coverage requires an ICD-10 diagnosis supported by your MAC’s Local Coverage Determination, and an unsupported diagnosis is a common denial cause.

An ABN does not prevent a denial. It lets you bill the patient when Medicare denies a test ordered for a non-covered diagnosis.

Pabau, the practice management software we build, checks required claim details before each 86038 claim is sent and tracks it through to payment.

CPT code 86038: Official descriptor and test overview

CPT code 86038 describes antinuclear antibody (ANA) testing by any method, as defined by the American Medical Association’s CPT code set. Indirect fluorescent antibody (IFA) testing is the common method, but ELISA and multiplex immunoassay results are reported under 86038 too. The test is qualitative: it reports whether antinuclear antibodies are present or absent. On a positive IFA result, the laboratory also identifies the fluorescence pattern (homogeneous, speckled, nucleolar, centromere). It does not report a quantitative titer.

The IFA method uses fluorescently labeled antibodies to detect binding to nuclear antigens on a substrate (typically HEp-2 cells). Positive screens are then reported with pattern information, which guides whether follow-on confirmatory testing is clinically warranted.

What CPT 86038 includes and what it excludes

The line between the screen, the titer and the specific antibody tests decides which code each result goes under.

Included under 86038:

• Qualitative antinuclear antibody testing by any method (IFA is the common method)
• Reporting of positive or negative result
• Pattern identification on positive IFA results (homogeneous, speckled, nucleolar, centromere, peripheral) as part of the screen interpretation

Excluded from 86038:

• Titer quantification, which is reported under 86039
• Specific antibody testing: anti-dsDNA is reported under 86225, and anti-Sm, anti-SSA and anti-SSB are reported under 86235, once per antibody

A lab may run the screen and then reflexively quantify the titer on a positive result. In that case, both 86038 and 86039 may be billable, but only with separate clinical documentation supporting each service. Bundling both without justification triggers NCCI edit review.

CPT 86038 vs 86039: Screen vs titer

CPT 86039 describes the ANA titer. It quantifies the antibody concentration on a positive screen and confirms the fluorescence pattern. The two codes describe distinct analytic steps — a screen and a measurement — so each result maps to one code.

Check the current NCCI edit file before billing both codes same-day. NCCI edits are updated quarterly by CMS, and the edit status between 86038 and 86039 can change. If an edit exists with a modifier indicator of “1,” appending the appropriate modifier with documented clinical justification allows both codes to process.

Related autoimmune CPT codes used alongside 86038

Rheumatology workups rarely order 86038 in isolation. The following codes are commonly co-ordered, and each has its own NCCI edit profile and medical necessity requirements. See the AAPC’s CPT code reference for full descriptors on each.

Panels that follow a positive ANA often add 86225 for anti-dsDNA and 86235 for each extractable nuclear antigen tested. These are distinct analytes and are generally billable together with 86038. Still, check the NCCI edit table for each pairing before claim submission. When the picture could be allergic rather than autoimmune, the provider may order 86003 instead.

ICD-10 codes that support medical necessity for CPT 86038

Medical necessity for CPT code 86038 is established by linking it to an ICD-10 diagnosis code that reflects the clinical indication. Medicare contractors apply LCD criteria, and a diagnosis outside the covered list is denied. Use the CDC’s ICD-10-CM web tool to confirm current code descriptions. Pabau’s ICD-10-CM code guides explain each diagnosis code in more depth.

LCD policies vary by Medicare Administrative Contractor (MAC) jurisdiction. A diagnosis accepted by Noridian may not be listed under Novitas or CGS. Always verify the active LCD number for your MAC before submitting claims with less common ICD-10 codes. When the ICD-10 code does not appear on the covered list, an Advance Beneficiary Notice (ABN) is needed to bill the patient if Medicare denies.

When SLE is already confirmed, the order usually carries M32.9. A rule-out workup with no confirmed diagnosis more often carries a symptom code such as R68.89.

Medicare reimbursement rate and fee schedule for CPT code 86038

Medicare pays CPT code 86038 under the Clinical Laboratory Fee Schedule (CLFS), not the Medicare Physician Fee Schedule (MPFS). That holds whether an independent laboratory or a physician office lab runs the test. The CLFS sets one national payment amount per code. Medicare pays the lower of that amount and the laboratory’s actual charge. Use the CMS Clinical Laboratory Fee Schedule files to confirm current rates for your setting.

Reimbursement rates for lab codes change annually. The CLFS rate for 86038 has historically fallen in the $10 to $20 range. Confirm it against the current CMS CLFS file rather than estimating from a prior year.

Documentation requirements and medical necessity for CPT 86038

Documentation is the other common denial trigger alongside ICD-10 linkage. The chart must support the medical necessity of ordering an ANA screen. For medical billing compliance, the record should carry each of these elements.

• Clinical signs and symptoms: joint pain, photosensitivity, unexplained rash, pleuritis, nephritis, or other features consistent with systemic autoimmune disease
• Ordering indication: documented clinical decision to evaluate for SLE, Sjogren’s, MCTD, or other connective tissue disease. A rule-out workup for symptoms unexplained by other diagnoses also qualifies.
• Provider credentials: ordering provider’s NPI and specialty documented on the requisition and claim
• LCD compliance: ICD-10 diagnosis must appear on the MAC’s covered diagnosis list for the relevant LCD
• ABN (if applicable): if the diagnosis is not on the LCD-covered list, an ABN is needed to bill the patient if Medicare denies. The patient signs it before the test, and the claim carries the GA modifier.

Payers audit 86038 claims when the ordering pattern shows high volume relative to practice specialty. A rheumatology practice ordering ANA screens is expected. A dermatology practice ordering them without a documented connective tissue disease workup attracts review.

Billing modifiers for CPT 86038

Two modifiers apply to CPT code 86038 in specific billing scenarios. Using either incorrectly increases denial risk and audit exposure.

Modifier -91 has a precise rule. It applies only when a separate specimen is collected on the same date of service for an independent clinical reason. CMS and the AMA both prohibit using -91 to reconfirm or verify an initial test result. Documentation must clearly state the clinical rationale for the repeat specimen.

How to bill CPT code 86038: Claim submission guidelines

A clean CPT 86038 claim gets five details right. A mismatch on any one of them can trigger a denial or an audit flag.

1. Place of service (POS): Use POS 81 (independent laboratory) for standalone labs. Use POS 11 (office) when your in-office lab performs and bills the test under its own CLIA number. A POS that doesn’t match the rendering provider’s enrollment can trigger a denial.
2. Ordering vs. performing provider: The ordering provider’s NPI goes in Box 17b of the CMS-1500. When you send the specimen to a reference lab, the performing lab goes in Box 32, with its NPI in Box 32a.
3. CLIA number: An in-office lab includes its CLIA certificate number in Box 23. Medicare requires it on laboratory claims.
4. ICD-10 linkage: Point Box 24E to the Box 21 letter of the supporting ICD-10-CM code from the table above. Leave unrelated diagnoses off that claim line.
5. Specimen handling: Record the collection date, time and transport conditions in the ordering note. Some payers check this during pre-payment review.

Modifiers -90 and -91 follow their own rules, which are covered in the billing modifiers section above.

Common claim denial reasons for CPT 86038 and how to prevent them

CPT code 86038 denials follow a few predictable patterns, and four questions asked before submission address each of them. For the denials that still get through, denial management workflows cut the rework.

• Non-covered ICD-10 diagnosis: The ICD-10 code submitted does not appear on the MAC’s LCD covered list. Prevention: cross-reference the active LCD for your MAC jurisdiction before billing. When you expect Medicare to deny, issue an ABN before the test.
• Denied test with no ABN on file: The denial comes from the non-covered diagnosis, and an ABN does not prevent it. A signed ABN shifts financial liability to the patient, and the GA modifier tells Medicare one is on file. Without it, the practice cannot bill the patient for the denied test. Prevention: trigger the ABN workflow whenever a non-LCD diagnosis is entered on the requisition, before the specimen is collected.
• Unbundling 86038 and 86039 without justification: Both codes billed same-day without documentation supporting separate clinical needs. Prevention: confirm the NCCI edit status for the pair. If you bill both, document the distinct clinical rationale in the chart.
• Reference lab billing errors with modifier -90: Modifier -90 applied incorrectly or the in-house and reference lab both bill the same code. Prevention: confirm billing responsibility in writing with the reference laboratory before the first claim.
• Ordering notes that don’t support the diagnosis: The clinical notes do not back up the diagnosis on the order. Prevention: implement a pre-order checklist requiring sign-and-symptom documentation linked to a covered ICD-10 before the requisition is released.

How Pabau supports clean CPT 86038 claims

Checking ICD-10 linkage, NCCI edits and LCD coverage by hand for every 86038 claim takes time, and errors creep in at volume. Re-keying patient and payer details and chasing claim status add more manual work on top.

Pabau keeps the patient’s insurer and policy on the patient record, so each invoice routes to the right payer without re-keying. Its claims software for practices runs validation checks every time you go to send a claim. If a required detail such as the member ID or a prior authorization number is missing, the claim can’t be sent until it’s fixed.

For US practices, Pabau connects to Claim.MD, its US clearinghouse partner. Each invoice becomes an electronic CMS-1500 claim for thousands of US payers. You can run a real-time eligibility check before the test is ordered, follow the claim’s status and post ERA remittances against the invoice.

Coding decisions stay with your team. Pabau doesn’t check a diagnosis against your MAC’s LCD or the NCCI table, so the four checks above still apply. What it removes is the re-keying and the chasing, and denied claims are flagged for rework in the same dashboard. See clean claim submission for the full pre-submission checklist.

Send cleaner CPT 86038 claims with less rework

Pabau checks required claim details before each 86038 claim is sent, then tracks it through Claim.MD to ERA posting. Billing staff spend less time re-keying and chasing claims.

Book a demo

Conclusion

CPT code 86038 itself rarely causes the denial. It fails on a diagnosis outside your MAC’s LCD, an 86039 billed without the NCCI check, or a -91 used to confirm a result.

So fix the order upstream. Put the LCD check and the ABN decision where the requisition is written, not at billing. An ABN signed after the test cannot shift liability to the patient.

The trade-off is a few minutes per order against a test you may never be able to bill. Book a demo to see how Pabau keeps 86038 claims, eligibility checks and ERA posting in one dashboard.

Continue your research

Need to understand how denials are tracked and resolved? Denial management in healthcare covers workflows for identifying, appealing, and preventing recurring claim rejections.

Want the full picture on medical billing processes? Revenue cycle management explained breaks down how each billing step connects from patient registration to payment posting.

Looking for denial code definitions? Denial codes in medical billing is a reference guide to common CARC and RARC codes returned on remittances.

Running an RA workup alongside the ANA? ICD-10 code M06.9: rheumatoid arthritis guide explains when the unspecified rheumatoid arthritis code supports the order.

Evaluating mixed connective tissue disease? ICD-10 code M35.1: other overlap syndromes covers the code used for MCTD and other overlap presentations.

Frequently asked questions